WO2002055014A2 - Therapeutic chroman compounds - Google Patents
Therapeutic chroman compounds Download PDFInfo
- Publication number
- WO2002055014A2 WO2002055014A2 PCT/SE2002/000070 SE0200070W WO02055014A2 WO 2002055014 A2 WO2002055014 A2 WO 2002055014A2 SE 0200070 W SE0200070 W SE 0200070W WO 02055014 A2 WO02055014 A2 WO 02055014A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sep
- optionally substituted
- piperazin
- methyl
- oxo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/24—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Quinoline Compounds (AREA)
- Pyrane Compounds (AREA)
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB02806562XA CN100384833C (zh) | 2001-01-16 | 2002-01-15 | 治疗用苯并二氢吡喃化合物 |
AU2002225551A AU2002225551B8 (en) | 2001-01-16 | 2002-01-15 | Therapeutic chroman compounds |
KR10-2003-7009435A KR20030070917A (ko) | 2001-01-16 | 2002-01-15 | 치료용 크로만 화합물 |
BR0206514-2A BR0206514A (pt) | 2001-01-16 | 2002-01-15 | Composto, método de tratamento de um ser humano ou animal que sofre de enxaqueca, uso do composto, composição farmacêutica, e, processo para preparar um composto |
MXPA03006261A MXPA03006261A (es) | 2001-01-16 | 2002-01-15 | Compuestos terapeuticos de cromano. |
US10/466,565 US20040110745A1 (en) | 2001-11-01 | 2002-01-15 | Therapeutic chroman compounds |
NZ526699A NZ526699A (en) | 2001-01-16 | 2002-01-15 | 8-amino derivatives and their use in treating migraine |
EP02715919A EP1353915A2 (en) | 2001-01-16 | 2002-01-15 | Therapeutic chroman compounds |
CA002434015A CA2434015A1 (en) | 2001-01-16 | 2002-01-15 | Therapeutic chroman compounds |
IL15660102A IL156601A0 (en) | 2001-01-16 | 2002-01-15 | Therapeutic chroman compounds |
JP2002555751A JP4280068B2 (ja) | 2001-01-16 | 2002-01-15 | 治療用クロマン化合物 |
IL156601A IL156601A (en) | 2001-01-16 | 2003-06-23 | Novel compounds and pharmaceutical preparations containing them |
NO20033205A NO20033205L (no) | 2001-01-16 | 2003-07-15 | Terapeutiske kromanforbindelser |
IL183183A IL183183A0 (en) | 2001-01-16 | 2007-05-14 | Therapeutic chroman compounds |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26210801P | 2001-01-16 | 2001-01-16 | |
US60/262,108 | 2001-01-16 | ||
SE0103646-6 | 2001-11-01 | ||
SE0103646A SE0103646D0 (sv) | 2001-11-01 | 2001-11-01 | Therapeutic chroman compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002055014A2 true WO2002055014A2 (en) | 2002-07-18 |
WO2002055014A3 WO2002055014A3 (en) | 2002-11-14 |
Family
ID=26655581
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE2002/000070 WO2002055014A2 (en) | 2001-01-16 | 2002-01-15 | Therapeutic chroman compounds |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1353915A2 (hu) |
JP (1) | JP4280068B2 (hu) |
KR (1) | KR20030070917A (hu) |
CN (1) | CN100384833C (hu) |
AR (1) | AR036327A1 (hu) |
AU (1) | AU2002225551B8 (hu) |
BR (1) | BR0206514A (hu) |
CA (1) | CA2434015A1 (hu) |
IL (3) | IL156601A0 (hu) |
MX (1) | MXPA03006261A (hu) |
MY (1) | MY138263A (hu) |
NO (1) | NO20033205L (hu) |
NZ (1) | NZ526699A (hu) |
SA (1) | SA02220709B1 (hu) |
WO (1) | WO2002055014A2 (hu) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1451158A1 (en) * | 2001-11-01 | 2004-09-01 | AstraZeneca AB | Therapeutic quinoline compounds with 5-ht-antagonistic properties |
WO2007094718A1 (en) * | 2006-02-14 | 2007-08-23 | Astrazeneca Ab | Radioligands for the 5 -ht1b receptor |
WO2007097697A1 (en) * | 2006-02-23 | 2007-08-30 | Astrazeneca Ab | Therapeutic quinoline compounds that are 5ht1b modulators |
JP2007528880A (ja) * | 2004-03-12 | 2007-10-18 | ハー・ルンドベック・アクチエゼルスカベット | 置換されたモルホリンおよびチオモルホリン誘導体 |
EP1945624A1 (en) * | 2005-11-04 | 2008-07-23 | Astra Zeneca AB | Chroman compounds as 5-ht1b antagonists |
US7767677B2 (en) | 2004-09-20 | 2010-08-03 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
US7777036B2 (en) | 2004-09-20 | 2010-08-17 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as therapeutic agents |
US7829712B2 (en) | 2004-09-20 | 2010-11-09 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase |
WO2010128345A1 (en) * | 2009-05-05 | 2010-11-11 | Szegedi Tudományegyetem | Kynurenic acid analogues, pharmaceutical compositions containing same and use of said compounds for the treatment of headache |
US7919496B2 (en) | 2004-09-20 | 2011-04-05 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes |
US7951805B2 (en) | 2004-09-20 | 2011-05-31 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase |
US8026360B2 (en) | 2004-09-20 | 2011-09-27 | Xenon Pharmaceuticals Inc. | Substituted pyridazines as stearoyl-CoA desaturase inhibitors |
US8071603B2 (en) | 2004-09-20 | 2011-12-06 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
US8110687B2 (en) | 2005-12-08 | 2012-02-07 | Millennium Pharmaceuticals, Inc. | Bicyclic compounds with kinase inhibitory activity |
US8541457B2 (en) | 2005-06-03 | 2013-09-24 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors |
US9630896B2 (en) | 2013-11-22 | 2017-04-25 | Tansna Therapeutics, Inc. | 2,5-dialkyl-4-H/halo/ether-phenol compounds |
US9975886B1 (en) | 2017-01-23 | 2018-05-22 | Cadent Therapeutics, Inc. | Potassium channel modulators |
US10774064B2 (en) | 2016-06-02 | 2020-09-15 | Cadent Therapeutics, Inc. | Potassium channel modulators |
US11993586B2 (en) | 2018-10-22 | 2024-05-28 | Novartis Ag | Crystalline forms of potassium channel modulators |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6344296B1 (en) | 1996-08-08 | 2002-02-05 | Hitachi Chemical Company, Ltd. | Graphite particles and lithium secondary battery using the same as negative electrode |
US7812206B2 (en) | 2006-03-21 | 2010-10-12 | Bp Corporation North America Inc. | Apparatus and process for the separation of solids and liquids |
US8530716B2 (en) | 2008-08-14 | 2013-09-10 | Bp Corporation North America Inc. | Melt-crystallization separation and purification process |
CN104262249A (zh) * | 2014-10-20 | 2015-01-07 | 云南民族大学 | 一种喹诺酮化合物的绿色高效制备方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8515389D0 (en) * | 1985-06-18 | 1985-07-17 | Ici Plc | Heterocyclic compounds |
US5112856A (en) * | 1986-08-15 | 1992-05-12 | Hoffmann-La Roche Inc. | Therapeutic treatment of intestinal inflammation by administration of 3,4-dihydro-2H-1-benzopyran derivatives |
SE8904361D0 (sv) * | 1989-12-22 | 1989-12-22 | Astra Ab | New chroman and thiochroman derivatives |
DE4140542A1 (de) * | 1991-12-09 | 1993-06-17 | Bayer Ag | Piperdylmethyl substituierte chormanderivate |
FR2761358B1 (fr) * | 1997-03-27 | 1999-05-07 | Adir | Nouveaux composes de n-aryl piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
SE9703378D0 (sv) * | 1997-09-18 | 1997-09-18 | Astra Ab | New compounds |
FR2782515B1 (fr) * | 1998-08-21 | 2000-09-22 | Adir | NOUVEAUX DERIVES DE L'INDANE-1-Ol, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT |
-
2002
- 2002-01-15 CN CNB02806562XA patent/CN100384833C/zh not_active Expired - Fee Related
- 2002-01-15 CA CA002434015A patent/CA2434015A1/en not_active Abandoned
- 2002-01-15 NZ NZ526699A patent/NZ526699A/en unknown
- 2002-01-15 IL IL15660102A patent/IL156601A0/xx unknown
- 2002-01-15 KR KR10-2003-7009435A patent/KR20030070917A/ko not_active Application Discontinuation
- 2002-01-15 EP EP02715919A patent/EP1353915A2/en not_active Withdrawn
- 2002-01-15 MX MXPA03006261A patent/MXPA03006261A/es active IP Right Grant
- 2002-01-15 BR BR0206514-2A patent/BR0206514A/pt not_active IP Right Cessation
- 2002-01-15 JP JP2002555751A patent/JP4280068B2/ja not_active Expired - Fee Related
- 2002-01-15 WO PCT/SE2002/000070 patent/WO2002055014A2/en active Application Filing
- 2002-01-15 AU AU2002225551A patent/AU2002225551B8/en not_active Ceased
- 2002-01-16 AR ARP020100142A patent/AR036327A1/es unknown
- 2002-01-16 MY MYPI20020159A patent/MY138263A/en unknown
- 2002-03-11 SA SA02220709A patent/SA02220709B1/ar unknown
-
2003
- 2003-06-23 IL IL156601A patent/IL156601A/en not_active IP Right Cessation
- 2003-07-15 NO NO20033205A patent/NO20033205L/no not_active Application Discontinuation
-
2007
- 2007-05-14 IL IL183183A patent/IL183183A0/en unknown
Non-Patent Citations (5)
Title |
---|
BARNES; SHARP, NEUROPHARMACOLOGY, vol. 38, 1999, pages 1083 - 1152 |
J. MED. CHEM, vol. 41, 1998, pages 1218 - 1235 |
J. MED. CHEM, vol. 42, 1999, pages 4981 - 5001 |
LAZARENO, S., METHODS IN MOLECULAR BIOLOGY, vol. 106, 1999, pages 231 - 245 |
ROBERTS ET AL., BR. J. PHARMACOL., vol. 117, 1996, pages 384 - 388 |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1451158A1 (en) * | 2001-11-01 | 2004-09-01 | AstraZeneca AB | Therapeutic quinoline compounds with 5-ht-antagonistic properties |
US8299075B2 (en) | 2004-03-12 | 2012-10-30 | H. Lundbeck A/S | Substituted thiomorpholine derivatives |
US8012962B2 (en) | 2004-03-12 | 2011-09-06 | H. Lundbeck A/S | Substituted thiomorpholine derivatives |
JP2007528880A (ja) * | 2004-03-12 | 2007-10-18 | ハー・ルンドベック・アクチエゼルスカベット | 置換されたモルホリンおよびチオモルホリン誘導体 |
US7767677B2 (en) | 2004-09-20 | 2010-08-03 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
US7951805B2 (en) | 2004-09-20 | 2011-05-31 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase |
US8071603B2 (en) | 2004-09-20 | 2011-12-06 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
US7777036B2 (en) | 2004-09-20 | 2010-08-17 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as therapeutic agents |
US7829712B2 (en) | 2004-09-20 | 2010-11-09 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase |
US8026360B2 (en) | 2004-09-20 | 2011-09-27 | Xenon Pharmaceuticals Inc. | Substituted pyridazines as stearoyl-CoA desaturase inhibitors |
US7919496B2 (en) | 2004-09-20 | 2011-04-05 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes |
US8541457B2 (en) | 2005-06-03 | 2013-09-24 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors |
EP1945624A1 (en) * | 2005-11-04 | 2008-07-23 | Astra Zeneca AB | Chroman compounds as 5-ht1b antagonists |
EP1945624A4 (en) * | 2005-11-04 | 2010-06-30 | Astrazeneca Ab | CHROMIN COMPOUNDS AS 5-HT1B ANTAGONISTS |
US8110687B2 (en) | 2005-12-08 | 2012-02-07 | Millennium Pharmaceuticals, Inc. | Bicyclic compounds with kinase inhibitory activity |
WO2007094718A1 (en) * | 2006-02-14 | 2007-08-23 | Astrazeneca Ab | Radioligands for the 5 -ht1b receptor |
WO2007097697A1 (en) * | 2006-02-23 | 2007-08-30 | Astrazeneca Ab | Therapeutic quinoline compounds that are 5ht1b modulators |
WO2010128345A1 (en) * | 2009-05-05 | 2010-11-11 | Szegedi Tudományegyetem | Kynurenic acid analogues, pharmaceutical compositions containing same and use of said compounds for the treatment of headache |
US9630896B2 (en) | 2013-11-22 | 2017-04-25 | Tansna Therapeutics, Inc. | 2,5-dialkyl-4-H/halo/ether-phenol compounds |
US10774064B2 (en) | 2016-06-02 | 2020-09-15 | Cadent Therapeutics, Inc. | Potassium channel modulators |
US9975886B1 (en) | 2017-01-23 | 2018-05-22 | Cadent Therapeutics, Inc. | Potassium channel modulators |
US10351553B2 (en) | 2017-01-23 | 2019-07-16 | Cadent Therapeutics, Inc. | Potassium channel modulators |
US10717728B2 (en) | 2017-01-23 | 2020-07-21 | Cadent Therapeutics, Inc. | Potassium channel modulators |
US11993586B2 (en) | 2018-10-22 | 2024-05-28 | Novartis Ag | Crystalline forms of potassium channel modulators |
Also Published As
Publication number | Publication date |
---|---|
SA02220709B1 (ar) | 2007-01-23 |
JP2004517130A (ja) | 2004-06-10 |
MXPA03006261A (es) | 2003-09-22 |
AU2002225551B2 (en) | 2008-04-03 |
WO2002055014A3 (en) | 2002-11-14 |
BR0206514A (pt) | 2004-01-06 |
NO20033205L (no) | 2003-09-02 |
EP1353915A2 (en) | 2003-10-22 |
MY138263A (en) | 2009-05-29 |
CN1524077A (zh) | 2004-08-25 |
CA2434015A1 (en) | 2002-07-18 |
AR036327A1 (es) | 2004-09-01 |
KR20030070917A (ko) | 2003-09-02 |
IL156601A0 (en) | 2004-01-04 |
NZ526699A (en) | 2005-03-24 |
CN100384833C (zh) | 2008-04-30 |
IL156601A (en) | 2009-06-15 |
IL183183A0 (en) | 2007-08-19 |
JP4280068B2 (ja) | 2009-06-17 |
AU2002225551B8 (en) | 2008-05-29 |
NO20033205D0 (no) | 2003-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002217742B2 (en) | Therapeutic heterocyclic compounds | |
AU2002217742A1 (en) | Therapeutic heterocyclic compounds | |
AU2002225551B2 (en) | Therapeutic chroman compounds | |
AU2002225551A1 (en) | Therapeutic chroman compounds | |
US20050085457A1 (en) | Therapeutic quinolone compounds with 5-ht-antagonistic properties | |
EP1353914A2 (en) | Therapeutic chromone compounds | |
US20050096312A1 (en) | Therapeutic quinolone compounds with 5-ht-antagonistic properties | |
US20040110745A1 (en) | Therapeutic chroman compounds | |
AU2002219770A1 (en) | Therapeutic chromone compounds | |
US20040082591A1 (en) | Therapeutic heterocyclic compounds | |
US20060019947A1 (en) | Therapeutic chromone compounds | |
NZ545374A (en) | Process for the production of therapeutic heterocyclic compounds | |
AU2002348559A1 (en) | Therapeutic quinolone compounds with 5-HT-antagonistic properties | |
AU2002348560A1 (en) | Therapeutic quinoline compounds with 5-HT-antagonistic properties |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002225551 Country of ref document: AU Ref document number: 156601 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 526699 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002715919 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2434015 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003/05318 Country of ref document: ZA Ref document number: 200305318 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/A/2003/006261 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002555751 Country of ref document: JP Ref document number: 1020037009435 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10466565 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1020037009435 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 02806562X Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2002715919 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 526699 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 526699 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 183183 Country of ref document: IL |